ICER seeks public input to guide selection of non-drug assessment topics for 2020

13 December 2019 - Suggestions for new topics and comments on initial list of potential topics are encouraged; input most helpful ...

Read more →

ICER finalises method adaptations for assessing potential cures and other high-impact single or short-term therapies

12 November 2019 - Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic ...

Read more →

ICER releases draft evidence report on acute migraine therapies

7 November 2019 - Public comment period on preliminary draft now open until 6 December 2019; requests to make oral comment ...

Read more →

Obscure model puts a price on good health—and drives down drug costs

4 November 2109 - Concept called QALY places dollar value on the health medicines can restore; ‘starting to influence decision-making’. ...

Read more →

ICER report finds oral GLP-1 semaglutide, at estimated net price, less cost-effective than SGLT-2 competitor empagliflozin as add-on therapy for type 2 diabetes

1 November 2019 - Semaglutide as add-on therapy to metformin achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than ...

Read more →

ICER posts draft scoping document for the assessment of treatments for non-alcoholic steatohepatitis

30 October 2019 - Document open to public comment until 20 November 20 2019. ...

Read more →

ICER issues final report and policy recommendations regarding additive treatments for cardiovascular disease

17 October 2019 - Independent appraisal committee votes that rivaroxaban and icosapent ethyl improve patient health at prices that achieve ...

Read more →

Some say a non-profit research group unfairly influences drug prices

16 October 2019 - Have you ever wondered how pharmaceutical companies decide whether that pill you take costs $3 or ...

Read more →

Accounting for hope: using ‘mean survival gain’ to price new cancer drugs

14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...

Read more →

ICER releases updated draft evidence report on rheumatoid arthritis therapies

11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December ...

Read more →

ICER to assess treatments for non-alcoholic steatohepatitis

8 October 2019 - Report will be subject of a Midwest CEPAC meeting in May 2020; Open Input now being accepted ...

Read more →

Humira, Rituxan top list of U.S. costliest drug price increases

8 October 2019 - AbbVie Inc’s arthritis drug Humira and Roche's cancer drug Rituxan top the list of seven treatments ...

Read more →

ICER identifies costliest US drug-price hikes that are not supported by new clinical evidence

8 October 2019 - In 2017 and 2018, out of nine identified drugs that had substantial price increases on top of ...

Read more →

ICER posts draft scoping document for the assessment of treatments for cystic fibrosis

30 September 2019 - Document open to public comment until 21 October 2019. ...

Read more →

ICER posts draft scoping document for the assessment of treatments for ulcerative colitis

27 September 2019 - Document open to public comment until 18 October 2019. ...

Read more →